Arcus Biosciences, Inc.

NYSE:RCUS

Biotechnology

Healthcare
$15.76 -0.39%

-$0.09 today

Market cap
$2.27B
Beta
0.84
P/E (TTM)
-8.2
EPS (TTM)
-$2.94
52W Low $7.91High $28.72

Volume 1.97M

Average 1.17M

RCUS Sales of Investments

Cash received from selling or redeeming investments.

Arcus Biosciences, Inc.NYSE: RCUS

Sales of Investments · Q2 FY2026 · quarter ended Jun 2026

Sales of investments declines year over year

Q2 FY2026 sales of investments of $234M fell 21.5% year over year, behind the -17.3% change in trailing-twelve-month sales of investments. Sequentially, it fell 11.4% from the prior quarter. Over 3 fiscal years it compounded at +11.0% a year.

Context

  • Sales of investments amounted to 463.2% of revenue in FY2025, up 89.1 pp from a year earlier.
  • Sales of investments increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -21.5% toward the trailing-twelve-month pace of -17.3%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$234M-11.4% QoQ
Last fiscal yearDec 2025
$1.14B+18.5% YoY
LTMJun 2026
$958M-17.3% YoY
Sales of Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-21.5%——
1 year+18.5%——
3-year CAGR+11.0%——
5-year CAGR——
10-year CAGR——

Sales of Investments history

USD · from the cash flow

Latest · FY2025
1.14B USD
Year-over-year change
+18.5%
4-year CAGR
+11.5%

Sales of Investments vs competitors

How RCUS compares with its peers on the latest reported figures

  • RCUS's LTM Jun 2026 sales of investments of $958M is the 2nd largest of the 9 companies compared; the peer median is $465.55M.
  • Its year-over-year change of -17.3% is the lowest of 7, against a peer median of +14.8%.
  • Sales of investments amounts to 818.8% of revenue for RCUS, versus a peer median of 524.7%.
RCUS Competitors Peer median
Sales of Investments for RCUS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AGIOAgios Pharmaceuticals, Inc.LTM Mar 2026$1.04B +40.3%-3.4%1567.4%
RCUSArcus Biosciences, Inc.LTM Jun 2026$958M -17.3%+11.0%818.8%
BEAMBeam Therapeutics Inc.LTM Jun 2026$818.71M +17.6%-11.0%524.7%
DNLIDenali Therapeutics Inc.LTM Jun 2026$799.11M -8.5%-10.7%22172.9%
VRDNViridian Therapeutics, Inc.LTM Jun 2026$556.71M -1.6%+70.7%782.7%
IBRXImmunityBio, Inc.LTM Sep 2026$374.39M +1501.0%—205.1%
COGTCogent Biosciences, Inc.LTM Jun 2026$337.64M +12.1%+68.9%—
LQDALiquidia CorporationLTM Jun 2026$0 ——0.0%
OCULOcular Therapeutix, Inc.LTM Mar 2026$0 ——0.0%
Peer median (excluding RCUS) $465.55M+14.8%-3.4%524.7%

Competitors are the stored peer set for RCUS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income52.83M(267M)(307M)(283M)(353M)
Depreciation & Amortization4M6M8M10M10M
Deferred Income Tax00000
Stock-Based Compensation55M65M73M76M60M
Change in Working Capital(375.62M)623M(71M)22M(194M)
Accounts Receivables(17.05M)704M15M28M9M
Inventory00000
Accounts Payables(4.77M)8M(1M)3M24M
Other Working Capital(353.8M)(89M)(85M)(9M)(227M)
Other Non-Cash Items7.62M11M(9M)5M(5M)
Operating Cash Flow(256.17M)438M(306M)(170M)(482M)
Capital Expenditures(26.08M)(6M)(24M)(6M)(2M)
Acquisitions (Net)00000
Purchases of Investments(718.87M)(1.24B)(788M)(1.04B)(1.08B)
Sales of Investments741.08M837M1.01B965M1.14B
Other Investing Activities0(3M)000
Investing Cash Flow(3.87M)(413M)194M(84M)66M
Debt Repayment5M0047M49M
Common Stock Issued232.35M23M25M228M439M
Common Stock Repurchased(6K)0000
Dividends Paid00000
Other Financing Activities010M8M2M0
Financing Cash Flow237.34M33M33M277M488M
Effect of Forex Changes(2.8M)0000
Net Change in Cash(25.5M)58M(79M)23M72M
Free Cash Flow(282.25M)432M(330M)(176M)(484M)

Arcus Biosciences, Inc.

NYSE:RCUS

Intrinsic Alpha fair value

Locked

Current Price

$15.76

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.